GlassScriptPhysician profile
Debra L Knuckles
NPI 1679610844
$8,727.21
in general payments reported to CMS, 2019-2025
34 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,010 · 2022: $2,151 · 2023: $1,935 · 2024: $1,433 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,566.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,864.28 | 2021-2024 | Relistor |
| Abbvie INC. | $1,345.29 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $1,296.85 | 2021-2025 | Xtampza, Belbuca |
| Azurity Pharmaceuticals, INC. | $467.62 | 2023-2025 | Horizant, Horizant |
| Pfizer INC. | $408.67 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $325.40 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $309.55 | 2022-2023 | Belsomra |
| Forte Bio-Pharma LLC | $247.90 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Arbor Pharmaceuticals, INC. | $228.83 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $223.09 | 2021-2025 | Ztlido |
| Redhill Biopharma INC. | $193.19 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $185.12 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $167.01 | 2022 | |
| Hikma Pharmaceuticals USA | $156.52 | 2021-2024 | Kloxxado |
| Uswm, LLC | $139.92 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $129.02 | 2025 | Evoke |
| Abbott Laboratories | $128.69 | 2021-2025 | Eterna |
| Novo Nordisk INC | $113.73 | 2022 | |
| Valinor Pharma, LLC | $103.42 | 2025 | Movantik |
| Eisai INC. | $97.25 | 2021 | |
| Ibsa Pharma INC. | $80.26 | 2023-2025 | Licart, Tirosint, Tirosint |
| Virtus Pharmaceuticals LLC | $70.67 | 2024-2025 | Levorphanol Tartrate |
| Biodelivery Sciences International, INC. | $61.18 | 2021 | |
| Masimo Corporation | $56.09 | 2023 | Na |
| Spr Therapeutics, INC | $49.82 | 2025 | Sprint Pns System |
| Vertex Pharmaceuticals Incorporated | $49.09 | 2024-2025 | |
| Electronic Waveform Lab, INC. | $45.73 | 2021 | |
| Grt US Holding, INC. | $38.59 | 2021 | |
| Boston Scientific Corporation | $36.08 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Almatica Pharma LLC | $27.28 | 2021 | |
| Bioventus LLC | $26.39 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.12 | 2022 | |
| Averitas Pharma INC. | $18.58 | 2023 | Qutenza |
| Mml US, INC. | $14.98 | 2023 | Reactiv8 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Knuckles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.